Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …

Purpose To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …

Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …

This study compared two schedules of low‐dose gemtuzumab ozogamicin (GO) as induction
monotherapy for untreated acute myeloid leukaemia in older patients unfit for intensive …

The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …

BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) in the elderly is
associated with low rates of response to conventional chemotherapy and long-term survival …

This trial tested the safety and efficacy of a regimen consisting of hydroxyurea followed by
azacitidine, 75 mg/m2 for 7 days, and gemtuzumab ozogamicin, 3 mg/m2 on day 8, in older …

Background Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of
acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy …

Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to
calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid …

Abstract 6 Aim. GO is a potent antibody-directed chemotherapy against CD33 antigen. Two
MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one …